治疗前血清铁蛋白浓度与肺癌患者预后相关性的Meta分析  

Association of the pretreatment serum ferritin concentration with prognosis in lung cancer patients:a meta-analysis

作　　者：王一帆[1] 金健[1] 李蔼建[1] 张彦[1] 宋波[1] 车国卫[2] WANG Yifan;JIN Jian;LI Aijian;ZHANG Yan;SONG Bo;CHE Guowei(Department of Thoracic Surgery,Affiliated Hospital of Chengdu University,Chengdu 610081,P.R.China;Department of Thoracic Surgery,West China Hospital,Sichuan University,Chengdu 610041,P.R.China)

机构地区：[1]成都大学附属医院胸外科,成都610081 [2]四川大学华西医院胸外科,成都610041

出　　处：《中国循证医学杂志》2020年第8期945-949,共5页Chinese Journal of Evidence-based Medicine

基　　金：四川省干部保健科研课题项目(编号:HZ2019-103)。

摘　　要：目的系统评价肺癌患者治疗前血清铁蛋白(serum ferritin,SF)浓度与肺癌预后的相关性。方法计算机检索PubMed、EMbase、Web of Science、CNKI、VIP和WanFang Data数据库,搜集有关肺癌患者SF浓度与肺癌预后相关性的队列研究,检索时限均从建库至2020年1月。由2名研究者独立筛选文献、提取数据并对纳入研究进行偏倚风险评价后,采用Stata 12.0软件进行Meta分析。结果共纳入8个队列研究,包括1002例肺癌患者。Meta分析结果显示,与治疗前SF较低的患者相比,治疗前SF浓度较高的肺癌患者的总生存期更短[HR=1.70,95%CI(1.06,2.73),P=0.029];针对不同病理类型的亚组分析显示,SF仅在小细胞肺癌患者中具有较高的预后价值[HR=4.78,95%CI(2.83,8.05),P<0.001]。结论治疗前SF浓度较高的肺癌患者总生存期更短,治疗前SF浓度可能是肺癌患者的预后影响因素,尤其针对小细胞肺癌患者。但受纳入研究质量和数量的限制,上述结论仍需更多前瞻性的高质量研究予以进一步验证。Objectives To systematically review the association between pretreatment serum ferritin(SF)concentration and prognosis in lung cancer patients.Methods Databases including PubMed,EMbase,Web of Science,CNKI,VIP and WanFang Data were electronically searched to identify cohort studies on the relationship between the pretreatment SF concentration and prognosis of lung cancer patients from inception to January,2020.Literature screening,data extraction and quality evaluation of included studies were independently performed by two reviewers.Then,meta-analysis was conducted by Stata 12.0 software.Results A total of 8 cohort studies involving 1002 lung cancer patients were included.The results of meta-analysis indicated that patients with higher pretreatment SF concentration had poorer overall survival(HR=1.70,95%CI 1.06 to 2.73,P=0.029)compared with patients with lower pretreatment SF concentration.Subgroup analysis based on the pathological type manifested showed that pretreatment SF concentration only had high prognostic value in small cell lung cancer patients(HR=4.78,95%CI 2.83 to 8.05,P<0.001).Conclusions Lung cancer patients with high pretreatment SF level have worse overall survival.Pretreatment SF concentration may serve as an independent prognostic factor in lung cancer,especially in small cell lung cancer.Due to the limited quality and quantity of included studies,more prospective well-designed studies are required to verify above conclusions.

关 键 词：血清铁蛋白 肺癌 预后 META分析 队列研究 

分 类 号：R734.2[医药卫生—肿瘤]